Trial Profile

A Single-Dose, Randomized, Placebo-Controlled, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jul 2024 Status changed from active, no longer recruiting to completed.
26 Feb 2024 Results assessing efficacy of ARS-2 in Urticaria Scores in Patients with Frequent Urticaria Flares presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
26 Feb 2024 According to an ARS Pharmaceuticals media release, data for neffy are being presented on February 26, at the 2024 American Academy of Allergy, Asthma and Immunology (AAAAI) in Washington.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com